PCSK9 and sleep apnea syndrome: According to our DMR analysis, HMGCR and PCSK9, which act by lowering serum LDL-C levels, were inversely associated with the risk of sleep apnea syndrome (OR = 0.627; 95% CI = 0.511–0.767; P = 6.30E−06) (OR = 0.775; 95% CI = 0.677–0.888; P = .0002).